TELA Bio, Inc. (NASDAQ: TELA) reported Q2 EPS of ($0.51), $0.05 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $18.45 million.

GUIDANCE:

TELA Bio, Inc. sees FY 2024 revenue of $74.5-76.5 million, versus the consensus of $75.407 million.

For earnings history and earnings-related data on TELA Bio, Inc. (TELA) click here.